Cresco Labs (CRLBF) Payables (2019 - 2026)

Cresco Labs' (CRLBF) quarterly Payables came in at $14.2 million in Q1 2026, down 48.13% on a QoQ basis from $27.3 million in Q4 2025.

Cresco Labs (CRLBF) Payables (2019 - 2026) Analysis & Trends

Cresco Labs (CRLBF) has 8 years of Payables data on file, last reported at $14.2 million in Q1 2026.

Quarterly Payables changed N/A year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (changed N/A YoY) and the FY2025 annual result came in at $27.3 million, changed N/A from the prior year.
Payables slipped to $14.2 million in Q1 2026, from $27.3 million in the prior quarter.
In the past five years, Payables ranged from a high of $62.5 million in Q1 2022 to a low of $14.2 million in Q1 2026.
A 5-year average of $36.4 million and a median of $39.1 million in 2024 frame the typical range for Payables.
The widest YoY moves for Payables: up 3.89% in 2022, down 3.89% in 2022.
Tracing CRLBF's Payables over 5 years: stood at $62.5 million in 2022, then slumped by 36.94% to $39.4 million in 2023, then grew by 5.09% to $41.4 million in 2024, then slumped by 34.02% to $27.3 million in 2025, then slumped by 48.13% to $14.2 million in 2026.
The last three Payables figures came in at $14.2 million (Q1 2026), $27.3 million (Q4 2025), and $41.4 million (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Haleon	44.00 Bn	43.04 Bn	-	-7.73 Bn
2	Teva Pharmaceutical Industries	43.30 Bn	39.65 Bn	2.15 Bn	2.72 Bn
3	Zoetis	31.78 Bn	30.10 Bn	1.05 Bn	673.00 Mn
4	Takeda Pharmaceutical	28.71 Bn	22.92 Bn	5.10 Bn	2.80 Bn
5	United Therapeutics	22.21 Bn	19.54 Bn	683.80 Mn	497.80 Mn
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	1.73 Bn
7	Neurocrine Biosciences	15.60 Bn	15.21 Bn	935.80 Mn	808.30 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	427.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	986.00 Mn
10	Cresco Labs	297.39 Mn	233.28 Mn	86.95 Mn	27.63 Mn

Download Data